Advocacy and Compliance Issues Impacting Dermatology in 2025.

IF 2.7 4区医学 Q3 DERMATOLOGY

Cutis Pub Date : 2025-06-01 DOI:10.12788/cutis.1218

Alina G Bridges, Nicole Werpachowski

引用次数: 0

Abstract

We review recent dermatology and dermatopathology advocacy successes resulting in the reversal of immunohistochemistry (IHC) stain reimbursement denials. We also highlight a new position statement on IHC utilization, explain modifications to the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and College of American Pathologists (CAP) laboratory director requirements, and outline critical legislative initiatives including support for federal payment reform for physicians.

查看原文本刊更多论文

2025年影响皮肤病学的宣传和合规问题。

我们回顾最近皮肤病学和皮肤病理学倡导成功导致逆转免疫组织化学（IHC）染色报销拒绝。我们还强调了一项关于IHC使用的新立场声明，解释了对1988年临床实验室改进修正案（CLIA）和美国病理学家学会（CAP）实验室主任要求的修改，并概述了关键的立法举措，包括支持联邦医生支付改革。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cutis 医学-皮肤病学

CiteScore

1.10

自引率

0.00%

发文量

191

审稿时长

6-12 weeks

期刊介绍： Published since 1965, Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner. The journal is published monthly and focuses on concise clinical articles that present the practical side of dermatology. Referenced in Index Medicus/MEDLINE, it is respected and enjoyed by both specialists and derm-active generalists, enabling its readers to get what they need quickly and efficiently. Furthermore, Cutis is read by more physicians actively involved in the day-to-day treatment of dermatologic conditions than any other dermatology publication. Covering a broad range of pertinent and timely topics, Cutis is written and edited by industry leaders. For information on article submissions, please see our Information for Authors.